EYEN Shares Are Trading Higher Today: What You Need To Know
EYEN Shares Are Trading Higher Today: What You Need To Know
Eyenovia Inc (NASDAQ:EYEN) shares are surging Monday in response to the company's announcement of the launch of a new FDA-approved ophthalmic drug in collaboration with Formosa Pharmaceuticals.
Eyenovia Inc（納斯達克股票代碼：EYEN）週一股價飆升，原因是該公司宣佈與臺塑製藥合作推出一種經美國食品藥品管理局批准的新眼科藥物。
Key Developments:
主要進展：
- Eyenovia and Formosa Pharma have launched APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%), the first FDA-approved ophthalmic drug using clobetasol propionate, a super-potent corticosteroid. The drug is designed for treating postoperative inflammation and pain following eye surgery.
- The ophthalmic steroid market in the U.S. is valued at approximately $1.3 billion, and nearly seven million ophthalmic surgeries are performed annually. Eyenovia's new product stands out due to its twice-daily dosing regimen, compared to up to four doses per day for other treatments, making it a cost-effective and more convenient option.
- Formosa Pharmaceuticals made its first shipment of the drug to the U.S. for commercialization, with Eyenovia expected to begin full-scale commercialization later in September 2024. This drug was developed using Formosa's proprietary APNT nanotechnology platform.
- The company has initiated pre-launch activities for the product, signaling momentum toward capturing market share in the growing ophthalmic sector.
- Eyenovia和臺塑製藥推出了 APP13007（丙酸氯倍他索眼用懸浮液，0.05％），這是美國食品藥品管理局批准的第一種使用超強皮質類固醇丙酸氯倍他索的眼科藥物。該藥物設計用於治療眼科手術後的術後炎症和疼痛。
- 美國的眼科類固醇市場價值約爲13億美元，每年進行近700萬次眼科手術。Eyenovia的新產品因其每天兩次的給藥方案而脫穎而出，而其他治療每天最多四劑，這使其成爲一種具有成本效益且更方便的選擇。
- 臺塑製藥首次向美國運送該藥物進行商業化，預計Eyenovia將於2024年9月晚些時候開始全面商業化。這種藥物是使用福爾摩沙專有的apNT納米技術平台開發的。
- 該公司已經啓動了該產品的上市前活動，這表明了在不斷增長的眼科領域佔據市場份額的勢頭。
What Else: This news is also trending across financial platforms and social media as investors speculate the product's market entry could significantly boost Eyenovia's revenues and market presence in the ophthalmic space.
還有什麼：這一消息在金融平台和社交媒體上也很流行，因爲投資者推測該產品的市場進入可能會顯著提高Eyenovia在眼科領域的收入和市場份額。
EYEN Price Action: Eyenovia's stock has spiked by 14.94%, reaching 0.57 cents at market close Monday, according to Benzinga pro.
EYEN價格走勢：據Benzinga專業人士稱，Eyenovia的股票已飆升14.94％，週一收盤時達到0.57美分。
- Do You Know What It Takes To Be 'Wealthy' When Retired? Here's What The Top 5% Of Retirees Have In Their Nest Eggs
- 你知道退休後變得 「富有」 需要什麼嗎？以下是前5％的退休人員的儲備金
Image Via Shutterstock.
圖片來自 Shutterstock。
譯文內容由第三人軟體翻譯。